Earlier this month, European regulators announced they were “pretty confident” vaccines employing this method could prevent B.1.617 incursions.
In a press conference on May 12, Marco Cavaleri, EMA vaccine strategy manager, said both mRNA and adenovirus-based candidates could prevent infection.
He said: “So far, overall, we are pretty confident that the vaccines will be effective against this variant.”
An additional note from the agency via Twitter said “promising evidence” points towards its success.
This post originally appeared on Daily Express :: Health Feed